Collaborator: Myriad Genetics

• Partially functional (hypomorphic) missense variants in BRCA2 are reduced penetrance pathogenic variants

  April 2, 2026

• Reduced penetrance BRCA1 and BRCA2 pathogenic variants in clinical germline genetic testing

• Reduced penetrance BRCA1 and BRCA2 pathogenic variants in clinical germline genetic testing

  April 2, 2026

• Always better when we’re together: A novel, collaborative multi-stakeholder coalition enhances national guidelines for hereditary cancer testing and detection

  Take home points: Clinical guidelines must evolve along with ongoing research findings. To assist this, the Inter-Organization Cancer Genetics Clinical Evidence Coalition (INTERACT) was established in 2020 among leading laboratory, industry, and patient groups. To date, INTERACT has submitted 12 letters to NCCN guidelines committees requesting changes, and has had 12 requested changes approved. INTERACT has impacted NCCN testing guidelines…

  April 2, 2026

• Germline Genetic Testing After Cancer Diagnosis